<DOC>
	<DOCNO>NCT00005783</DOCNO>
	<brief_summary>Sickle cell anemia genetic disorder result single nucleotide substitution codon 6 beta-globin gene , homozygous state , produce abnormal hemoglobin prone polymer formation deoxygenate . The polymerized hemoglobin lead impaired deformability sickling red blood cell subsequently lodge end-arterioles produce classic prominent feature disorder , repeat vasoocclusive crisis . Despite knowledge precise genetic defect decade , recently therapeutic impact base upon knowledge clear benefit treatment hydroxyurea , cell cycle-specific agent administer induce production fetal hemoglobin ( HbF ) stimulate gamma-globin synthesis , report patient sickle cell disease ( SCD ) . The reduction frequency severity vasoocclusive crisis see attributed increase HbF level responsive patient . While majority patient demonstrate rise HbF , patient benefit treatment . Given result , alternative agent also stimulate production HbF warrant investigation treatment SCD . Recombinant-methionyl human stem cell factor ( SCF ) hematopoietic growth factor activity immature hematopoietic progenitor cell . SCF stimulate production HbF vitro vivo , effect attainable without myelosuppression associate hydroxyurea . In phase I/II trial , administer SCF dose escalate fashion patient sickling disorder . Parameters measure HbF level , F cell level , peripheral blood CD34 level , frequency , duration , severity vasoocclusive crisis , toxicity .</brief_summary>
	<brief_title>A Phase I/II Trial Recombinant-Methionyl Human Stem Cell Factor ( SCF ) Adult Patients With Sickling Disorders</brief_title>
	<detailed_description>Sickle cell anemia genetic disorder result single nucleotide substitution codon 6 beta-globin gene , homozygous state , produce abnormal hemoglobin prone polymer formation deoxygenate . The polymerized hemoglobin lead impaired deformability sickling red blood cell subsequently lodge end-arterioles produce classic prominent feature disorder , repeat vasoocclusive crisis . Despite knowledge precise genetic defect decade , recently therapeutic impact base upon knowledge clear benefit treatment hydroxyurea , cell cycle-specific agent administer induce production fetal hemoglobin ( HbF ) stimulate gamma-globin synthesis , report patient sickle cell disease ( SCD ) . The reduction frequency severity vasoocclusive crisis see attributed increase HbF level responsive patient . While majority patient demonstrate rise HbF , patient benefit treatment . Given result , alternative agent also stimulate production HbF warrant investigation treatment SCD . Recombinant-methionyl human stem cell factor ( SCF ) hematopoietic growth factor activity immature hematopoietic progenitor cell . SCF stimulate production HbF vitro vivo , effect attainable without myelosuppression associate hydroxyurea . In phase I/II trial , administer SCF dose escalate fashion patient sickling disorder . Parameters measure HbF level , F cell level , peripheral blood CD34 level , frequency , duration , severity vasoocclusive crisis , toxicity .</detailed_description>
	<mesh_term>Anemia , Sickle Cell</mesh_term>
	<mesh_term>Hemoglobin SC Disease</mesh_term>
	<criteria>INCLUSION CRITERIA : Patients Hb SS , Sbetathal , SD , SOArab Age great equal 18 year . Patient must previous neurologic event ( either symptomatic find image alone ) . More one painful crisis per year last 2 year , require hospitalization . A previous acute chest syndrome . Evidence renal damage creatinine clearance great 50 percent normal . Red cell alloimmunization . Bilateral retinopathy . Osteonecrosis multiple bone . Unilateral bilateral leg ulcer . Patients fail course hydroxyurea decline take hydroxyurea . Able give inform consent . No active sickle cell crisis acute chest syndrome . No active uncontrolled infection . No hydroxyurea , erythropoietin , and/or arginine butyrate therapy previous month . No patient receive hypertransfusion therapy . No current treatment ( within 2 week ) hematopoietic growth factor . No allergy E. coli derive product . No history seasonal recurrent asthma within 5 precede year . No asthmatic symptom ( e.g . wheeze ) relate current respiratory tract infection . No significant IgEmediated hypersensitivity ( include limit allergic rhinitis , allergic eczema , anaphylactic reaction , congenital acquire angioedema , urticaria , ) . An isolated episode urticaria occur within 5 year contraindication . Patients drug allergy manifest solely rash exclude . No concurrent use betaadrenergic block agent . No concurrent use monoamine oxidase inhibitor . No significant comorbid condition include uncontrolled hypertension , congestive heart failure ( great NY class II ) , poorly control diabetes mellitus , significant coronary artery disease recent myocardial infarction angioplasty ( within previous 6 month ) . No pregnancy , breast feeding , unwillingness use contraception . No concurrent use investigational product .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2000</verification_date>
	<keyword>Fetal Hemoglobin</keyword>
	<keyword>Hematopoietic Growth Factor</keyword>
	<keyword>Peripheral Blood CD34 Cells</keyword>
	<keyword>Vasoocclusive Crisis</keyword>
	<keyword>Sickle Cell Anemia</keyword>
	<keyword>Sickle Cell Disease</keyword>
	<keyword>Sickle Cell Disorder</keyword>
</DOC>